Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
AstraZeneca plc, a British-Swedish pharmaceutical and biotechnology company, is reportedly withdrawing its COVID-19 vaccine worldwide. The company made the decision months after admitting in court there is a rare side effect.
But then again, according to Channel News Asia, AstraZeneca did not say this was the reason for the pullout of the vaccines. Rather, the company said it was due to “commercial reasons.”
Taking Back the COVID-19 Vaccines Years After Release
AstraZeneca said on Tuesday, May 7, the withdrawal of its vaccines around the world is already underway. It stressed that this is due to a "surplus of available updated vaccines" since the pandemic.
Moreover, the pharmaceutical and biotech firm announced it would also retract the vaccine Vaxzevria's marketing authorizations in Europe. AstraZeneca added that it is no longer producing its COVID-19 vaccine, so supply to the market has also stopped.
“As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines,” the company’s spokesman said in a statement. “This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.”
Reported Side Effects of Vaxzevria
AstraZeneca reportedly admitted in court documents that the vaccine has side effects like low platelet counts and blood clots. British newspapers stated that based on legal documents, the company's vaccine may cause TTS, but in very rare cases. World Health Organization (WHO), said this condition called Thrombosis with Thrombocytopenia Syndrome is a serious and life-threatening negative effect.
“It is admitted that the AZ vaccine can, in very rare cases, cause TTS,” AstraZeneca said in court documents in February. “The causal mechanism is not known.”
UK’s The Independent reported that AstraZeneca’s admission came after it was sued in the U.K. The class action lawsuits alleged that the company’s vaccine caused deaths and severe injuries, and claimants are seeking damages up to £100 million for around 50 supposed victims.
Photo by: Mufid Majnun/Unsplash
